News
Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...
Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...
As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...
Hosted on MSN10mon
Gilead’s lenacapavir: HIV prospects strongest in long-acting ... - MSNGilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, including with Merck’s islatravir, experts said.
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
3d
The World from PRX on MSNPEPFAR and the future of the global fight against HIVPEPFAR was launched in 2003 to stop the spread of HIV in Africa. Now, although some funding remains for the program, many of ...
A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by. Presented ...
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results